Editas Medicine (EDIT) Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Revenue data on file, last reported at $7.5 million in Q3 2025.

• On a quarterly basis, Revenue rose 12265.57% year-over-year to $7.5 million in Q3 2025; TTM through Sep 2025 was $46.4 million, a 24.9% decrease from a year earlier, with the FY2024 full-year figure at $32.3 million, down 58.64% from the prior year.
• Revenue for Q3 2025 stood at $7.5 million, up from $3.6 million in the prior quarter.
• Over the last five years, Revenue for EDIT reached as high as $60.0 million in Q4 2023 and fell as low as $42000.0 in Q3 2022.
• Historically, Revenue has averaged $9.0 million across 5 years, with a median of $6.2 million in 2021.
• Across the five-year window, Revenue slumped 99.32% in 2022 and surged 12604.76% in 2023, its largest moves.
• Year by year, Revenue stood at $12.5 million in 2021, then plunged by 47.58% to $6.5 million in 2022, then soared by 818.74% to $60.0 million in 2023, then sank by 49.03% to $30.6 million in 2024, then tumbled by 75.35% to $7.5 million in 2025.
• Per Business Quant data, the three most recent Revenue figures were $7.5 million in Q3 2025, $3.6 million in Q2 2025, and $4.7 million in Q1 2025.